Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 390Endometrial Neoplasms 223Uterine Cervical Neoplasms 217Breast Neoplasms 116Fallopian Tube Neoplasms 105Colorectal Neoplasms 91Carcinoma, Non-Small-Cell Lung 83Neoplasms 70Pancreatic Neoplasms 63Stomach Neoplasms 57Neoplasm Metastasis 54Prostatic Neoplasms 53Lung Neoplasms 49Melanoma 46Carcinoma, Ovarian Epithelial 44Triple Negative Breast Neoplasms 41Squamous Cell Carcinoma of Head and Neck 37Esophageal Neoplasms 37Carcinoma, Renal Cell 37Colonic Neoplasms 33Urinary Bladder Neoplasms 31Uterine Neoplasms 30Peritoneal Neoplasms 30Head and Neck Neoplasms 29Vulvar Neoplasms 28Carcinoma, Hepatocellular 28Small Cell Lung Carcinoma 25Carcinoma, Transitional Cell 25Uterine Cervical Dysplasia 22Sarcoma 20

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Gynecologic × 90 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡